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Abstract
Background: This study evaluated the prognosis of patients with extensive-stage small-cell lung cancer (ES-SCLC)
that may be associated with timing of thoracic radiotherapy (TRT).
Methods: ES-SCLC patients (n = 232) without progression were retrospectively analyzed after first-line induction
chemotherapy. Patients in the TRT group were stratified as early-TRT (ERT; ≤3 cycles of induction chemotherapy
received prior to TRT, n = 65) or late-TRT (LRT; >3 cycles, n = 122). To avoid selection bias, we conducted Propensity
Score Matching (PSM) for patients. Overall survival (OS), progression-free survival (PFS), and locoregional
recurrence-free survival (LRRFS) were assessed and compared.
Results: Overall, the median survival time, PFS, and LRRFS were 13.2, 8.7, and 14.6 months, respectively. After matching
by PSM, there were 45 patients total in the TRT/non-TRT groups, and 56 patients total in the ERT/LRT groups. OS, PFS,
and LRRFS were significantly longer in the TRT group than the non-TRT group (P < 0.001, all). However, between the
ERT and LRT groups these survival parameters were similar (P > 0.05, all).
Conclusion: For ES-SCLC patients without progression, the addition of TRT after first-line chemotherapy benefited
survival greatly. Early TRT showed no significant benefit over late TRT.
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Introduction
Small-cell lung cancer (SCLC) is well known for its
aggressiveness and high propensity to metastasize [1, 2].
Although SCLC only accounts for 13–20% of all lung
cancers [3], but it is still responsible for up to 40,000
deaths every year all over the world [4]. According to
the new tumor-node-metastasis (TNM) version 7 staging
system, Extensive-stage small-cell lung cancer (ES-
SCLC) is defined as the IV stage small cell lung cancer
and IIIB stage small cell lung caner which has metastatic
nodes outside the thorax and cannot be safely
encompassed within a tolerable radiotherapy treatment
plan [5]. Patients with ES-SCLC always have a poor
prognosis and are generally treated palliatively, although
SCLC is highly sensitive to chemotherapy and radiation
[6]. The current standard treatment for ES-SCLC is
platinum-based first-line chemotherapy, which has
remained unchanged over the past three decades [2].
Numerous studies were conducted to assess whether the
addition of thoracic radiotherapy (TRT) to chemother-
apy in the treatment of ES-SCLC was beneficial,
although many of these studies have shown that TRT
may improve patient outcomes significantly [7–10].
Studies of limited-stage SCLC (LS-SCLC) suggest that
early TRT with concurrent chemoradiotherapy (CCRT)
can improve survival [11–13], but such studies for
ES-SCLC are lacking. In the present study, we retro-
spectively evaluated the efficacy and prognosis associated
with the timing of TRT within the chemotherapy
regime, in a large population of ES-SCLC patients.
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After approval by Human Investigation Committee of
our cancer hospital, we identified all patients with
ES-SCLC by thoracic computed tomography (CT) and
positron emission tomography-computed tomography
(PET-CT), confirmed and treated at our cancer hospital,
between 1 January 2011, and 31 December 2015. All of
them received first-line chemotherapy. We excluded all
patients with incomplete medical records, who experi-
enced progression after chemotherapy, or who were lost
to follow-up.
In total, we collected data of 232 patients with ES-
SCLC without progression after first-line induction
chemotherapy. These patients were apportioned to a
TRT treatment group and non-TRT treatment group.
The TRT treatment group was further stratified accord-
ing to the timing of TRT treatment, as early-TRT (ERT)
or late-TRT (LRT). In addition, the electronic medical
record was used to obtain clinical information regarding
gender, age, KPS, and number of metastases. Both treat-
ment factors and clinical factors were included in the
survival analysis.
Chemotherapy
Patients received etoposide + cisplatin/etoposide + carbo-
platin (EP/EC) first-line induction chemotherapy:
etoposide 100 mg/m2 on days 1–5, combined with
cisplatin 30 mg/m2 on days 1–3 or area under the curve
(AUC)-based carboplatin dosing (AUC = 6). Every
21 days was a chemotherapy cycle. The median number
of chemotherapy cycles was six.
Radiotherapy
Radiotherapy planning was performed with a Philips
Pinnacle3 treatment planning system (Philips Medical
Systems, USA). For all patients, gross tumor volume was
identified based on the CT image, and included the
tumor and the metastatic lymph nodes, Clinical target
volume was based on the gross tumor volume, but also
included the primary tumor bed, and metastatic lymph
nodes before chemotherapy. The distance from the mar-
gin of the gross tumor volume to the clinical target vol-
ume was 5 mm. The distance from the margin of the
clinical target volume to the planning target volume was
5–10 mm. The radiation dose was 45–60 Gy in 15–30
fractions, 1.8–3 Gy per fraction, one fraction per day.
There were 187 patients who received radiotherapy: 177
of them received intensity-modulated radiation therapy;
6 of them received 3D conformal radiotherapy; and 4 of
them received stereotactic radiotherapy, the radiation
dose was 45-60Gy in 8–15 fractions. Other than TRT, 70
patients received radiotherapy for metastatic sites, and
the radiation dose was 30–45 Gy in 10–15 fractions, one
fraction per day. There were 26 patients who received
prophylactic cranial irradiation (PCI); all of them re-
ceived PCI after TRT, the radiation dose of PCI was
25 Gy in 10 fractions [14], one fraction per day.
Different timing of TRT
For analysis, the study population (n = 232) was divided
into a TRT group (n = 187) and a non-TRT group (n = 45).
Patients in the TRT group were stratified by the number
of induction chemotherapy cycles they received prior to
TRT. According to the previous research [15], we defined
ERT as receiving TRT before or at the third cycle of
chemotherapy, LRT was receiving TRT after the third
cycle of chemotherapy. Specifically, the ERT group (≤3 cy-
cles, n = 65) and the LRT group (>3 cycles, n = 122).
Endpoint
Overall survival (OS) was estimated from the date of
pathological diagnosis to the date of death for any
reason or last follow-up. Progression-free survival
(PFS) was from the date of receiving treatment to
the date of disease progression or the date of death
for any reason or last follow-up. Locoregional
recurrence-free survival (LRRFS) was estimated from
the date of receiving treatment to the date of local
recurrence or the date of death for any reason or
last follow-up.
Criteria for evaluating therapeutic effect
The response rate was evaluated by chest CT scans
1 month after completion of TRT. In accordance with
Response Evaluation Criteria in Solid Tumors version 1.1
(RECIST v. 1.1), short-term efficacy was considered a
complete response, partial response, stable disease, or pro-
gressive disease. Immeasurable lesions (such as bone
metastasis sites, or malignant pleural effusion) were
generally not evaluated, unless involved in disease
progression.
Evaluation of therapy-associated toxicity
Toxic effects due to the therapy were assessed according to
the National Cancer Institute Common Toxicity Criteria
version 4. These included leukopenia, thrombocytopenia,
anemia, nausea, and vomiting. Radiation-induced pneu-
monitis and esophagitis were also evaluated.
Statistical analysis
Clinical characteristics were compared using the chi-
squared test, Kaplan-Meier curves were created for OS,
PFS, and LRRFS. The Cox proportional hazards model
was used to examine factors associated with increased
hazard of death. All statistical analyses were performed
using SPSS 18.0 software (SPSS, Chicago, IL, USA) and R
2.8.0 statistical package. Because of the nonrandomized
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nature of this study, the ERT and LRT groups were
matched for possible confounding variables: gender,
age, KPS, smoking index, family history of neoplasm,
weight loss, PCI and number of metastases ≥2, we
preformed PSM with logistic regression estimation
algorithm and nearest neighbor matching algorithm,
and the caliper width was 0.2, matching 1:1. A group
of 187 patients with RT was matched to 45 patients
with non-RT, and another group of 122 patients with
LRT was matched to 65 patients with ERT, based on
the following baseline characteristics: age, gender,
smoking index, weight loss, KPS, number of metasta-




A total of 407 patients with pathologically diagnosed ES-
SCLC were treated at our cancer hospital between 1
January 2011 and 31 December 2015. All of them
received first-line chemotherapy. Ninety patients were
excluded from the study because of disease progression
after chemotherapy, and 85 were lost to follow-up.
Finally, the present analysis included 232 patients.
The clinical characteristics of the study cohort are
listed in Table 1.
Univariate and multivariate cox proportional hazard
analysis
Univariate analysis revealed that gender, PCI, number of
metastases ≥ 2, and TRT were significantly important to
OS. These significant variables were then put into a
multivariate Cox proportional hazard analysis and the
results showed that only TRT (odds ratio [OR], 0.374;
95% confidence interval [CI], 0.262–0.532, P < 0.001)
retained its statistical significance (Table 1).
Survival outcomes
For the entire study population, the median survival
time was 13.2 months (95% CI 11.3–17.9 months);
the OS rates at 6 and 12 months were 86.5 and
55.6%, respectively. The median PFS was 8.7 months
(95% CI 7.6–9.7 months); the PFS rates at 6 and
12 months were 76.1 and 34.6%. The median LRRFS
was 14.6 months (95% CI 11.6–14.8 months); the
LRRFS rates at 6 and 12 months were 80.0 and
56.9%.
The patients of the TRT and non-TRT, ERT, and LRT
groups were comparable with respect to gender, age,
smoking index, family history of neoplasm, weight loss
KPS, number of metastases ≥ 2, and PCI after propensity
score matching (Table 2 and Table 3). Importantly, the
characteristics listed in Tables 2 and Table 3 between the
Table 1 Clinical characteristics and survival-related factors of 232 patients with ES-SCLC in univariate and multivariate analysis
Univariate Analysis Multivariate Analysis
Patients, n (%) MST, mo P OR (95% CI) P
Age, y ≥65 64 (27.6) 13.0 0.313
<65 168 (72.4) 13.8
Gender Male 182 (78.4) 12.4 0.027 0.798 (0.510–1.248) 0.323
Female 50 (21.6) 19.3
KPS ≥80 215 (92.7) 13.8 0.296
<80 17 (7.3) 9.7
Smoking Yes 188 (81.0) 12.8 0.191
No 44 (19.0) 16.3
PCI Yes 26 (11.2) 22.3 0.010 0.587 (0.340–1.015) 0.057
No 206 (88.8) 12.1
Distant metastasis Yes 200 (86.2) 14.7 0.108
No 32 (13.8) 18.9
Number of metastases≥ 2 Yes 151 (65.1) 12.1 0.037 1.443 (0.860–2.422) 0.165
No 81 (34.9) 15.8
Weight loss Yes 27 (11.6) 11.6 0.304
No 205 (88.4) 13.8
TRT Yes 187 (80.6) 15.0 <0.001 0.374 (0.262–0.532) <0.001
No 45 (19.4) 8.3
TRT ERT 65 (28.0) 14.6 0.720 1.185 (0.814–1.727) 0.376
LRT 122 (52.6) 15.4
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TRT and non-TRT, ERT, and LRT groups were not sig-
nificantly different after PSM.
Relative to the non-TRT group, patients who received
TRT experienced improved OS, (17.7 mo cf. 11.3 mo),
PFS (9.8 mo cf. 6.3 mo), and LRRFS (16.2 mo cf. 6.3 mo;
P < 0.001, all; Fig. 1, Table 4). The ERT and LRT groups
were comparable in OS (16.4 mo cf. 14.5 mo; P = 0.272),
PFS (8.0 mo cf. 11.7 mo; P = 0.226), and LRRFS (25.3 mo
cf. 19.2 mo; P = 0.498; Fig. 2, Table 4).
Not only with regard to 3 cycles of induction chemo-
therapy, the OS, PFS and LRRFS of patients who
received different cycles of induction chemotherapy were
Table 2 Clinical characteristics of 232 patients in RT and non-RT groups after propensity score matching
Before matching After matching
RTa non-RTb P RTc non-RTd P
Gender Male 146 36 0.843 32 36 0.462
Female 41 9 13 9
Age, y ≥65 50 14 0.580 10 14 0.475
<65 137 31 35 31
KPS ≥80 174 41 0.749 42 41 1.000
<80 13 4 3 4
Smoking index ≥400 146 35 1.000 34 35 1.000
<400 41 10 11 10
Family history of neoplasm Yes 39 8 0.836 14 8 0.220
No 148 37 31 37
Weight loss Yes 25 2 0.121 4 2 0.677
No 162 43 41 43
PCI Yes 25 1 0.034 2 1 1.000
No 162 44 43 44
Number of metastases ≥2 Yes 21 11 0.029 8 11 0.606
No 166 34 37 34
an = 187; bn = 45; cn = 45; dn = 45
Table 3 Clinical characteristics of 187 patients in the ERT and LRT groups after propensity score matching
Before matching After matching
ERTa LRTb P ERTc LRTd P
Gender Male 51 95 0.541 44 44 1.000
Female 14 27 12 12
Age, y ≥65 20 30 0.389 19 18 1.000
<65 45 92 37 38
KPS ≥80 62 112 0.548 53 54 1.000
<80 3 10 3 2
Smoking index ≥400 51 95 1.000 45 43 0.818
<400 14 27 11 13
Family history of neoplasm Yes 8 31 0.039 8 9 1.000
No 57 91 48 47
Weight loss Yes 6 19 0.265 6 6 1.000
No 59 103 50 50
PCI Yes 15 10 0.006 7 8 1.000
No 50 112 49 48
Number of metastases ≥2 Yes 11 20 1.000 9 12 0.629
NO 54 102 47 44
an = 65; bn = 122; cn = 56; dn = 56
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similar (Table 5). It seems that patients in the LRT group
had better OS and PFS, and patients in the ERT group
had better LRRFS; but the difference was not statistically
significant.
Toxic effects
Side effects were evaluated according to World Health
Organization standards. In the present study, side effects
of grade II and above (hematologic toxicity, gastrointes-
tinal toxicity, acute radiation-induced pneumonitis, and
esophagitis) were defined as toxic effects. The toxic ef-
fects of the TRT group were much greater than that of
the non-TRT group (86.1 and 72.6%, P = 0.031). However
the severe toxic effects (grade-III and above) of these
groups were similar (33.6 and 29.2%, P = 0.105). In the
TRT group, the incidence rates of acute radiation-
induced pneumonitis or esophagitis were 9.1 and 11.8%,
respectively. In the ERT and LER group, severe toxic
effects were also similar (33.7 and 31.1%, P = 0.422).
Discussion
This report from a single-institution study analyzed a
cohort of patients with ES-SCLC who had not experi-
enced progression after first-line induction chemother-
apy. Our results show that TRT after induction
chemotherapy could increase survival, reduce relapse,
and improve local control in patients. Receiving ERT
(with 3 or fewer chemotherapy cycles) was not associ-
ated with any difference in prognosis compared with
LRT (more than 3 chemotherapy cycles).
For LS-SCLC, the role of TRT to improve survival is
well established, but for ES-SCLC, the ability of TRT is
still controversial [16]. At present, the basic treatment
strategy for ES-SCLC patients rests on chemotherapy, in
accordance with the old ACCP guideline, TRT can be
considered after effective chemotherapy in selected pa-
tients [17, 18]. A well-known prospective randomized
clinical trial has studied TRT in the treatment of ES-
SCLC, Slotman et al. [7] demonstrated that TRT may
improve patients’ outcomes significantly, but in their
research, they failed to analyze the 1-year overall
survival, and the radiation dose in the study was 30Gy in
10fractions. Comparing with Slotman’s research, our
study improved the radiation dose, and we finally ana-
lyzed the 1-year OS, PFS and LRRFS. According to
previous reports, more than half of ES-SCLC patients
experienced thoracic failure after effective chemotherapy
[19]. A prospective study in Canada, Yee et al. [20]
demonstrated that TRT might increase the local control
rate to prolong survival. There is also evidence that post-
operative consolidative TRT for SCLC patients can
greatly lower the local recurrence rate and therefore im-
prove survival [21, 22]. In the present study, and we ana-
lyzed 112 patients after PSM, the OS, PFS, and LRRFS
Fig. 1 Survival rates of the TRT and non-TRT groups. Relative to patients in the non-TRT group, the survival rates of patients who received TRT
showed improved (a) OS, (b) PFS, and (c) LRRFS
Table 4 Survival rates of the TRT, non-TRT, ERT, and LRT groups
OS PFS LRRFS
Overall, mo (95% CI) 1-year, % Overall, mo (95% CI) 1-year, % Overall, mo (95% CI) 1-year, %
TRT 17.7 (14.1-18.8) 57.9 9.8 (8.4–11.3) 45.9 16.2 (13.5–24.9) 72.6
Non-TRT 11.3 (9.8–12.7) 27.3 6.3 (5.0–7.0) 9.3 6.3 (5.6–7.0) 10.2
P <0.001 – <0.001 – <0.001 –
ERT 16.4 (13.4–18.4) 66.2 8.0 (7.0–9.0) 34.2 25.3 (21.5–27.9) 69.8
LRT 14.5 (12.2–17.0) 60.5 11.7 (9.1–13.4) 44.1 19.2 (13.1–23.1) 63.8
P 0.272 – 0.226 – 0.498 –
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were all significantly better than that of patients who did
not receive TRT (P < 0.01). In addition, rates of severe
toxicity were not higher in the radiotherapy group.
SCLC is chemosensitive, therefore, effective chemother-
apy can produce rapid responses with sometimes striking
improvements in symptoms [3]. In the American College
of Chest Physicians (ACCP) and National Comprehensive
Cancer Network (NCCN) guidelines, ES-SCLC patients
are advised to receive 4–6 cycles of first-line chemother-
apy [18, 23]. Considering that LS-SCLC patients can bene-
fit from early TRT after 2–3 cycles chemotherapy [24], is
the timing of TRT in the treatment of ES-SCLC also
important? The present study showed no evidence of a
difference in OS, PFS, or LRRFS between patients who
received early or late TRT. We conjecture that the differ-
ence may be associated with differences between LS- and
ES-SCLC, the tumor of ES-SCLC is not entirely localized
to the lungs, but always has distant organ metastases [8].
TRT is more powerful in improving local control than
systemic control, and better local control surely can
reduce the risk of distant metastases. However, for
ES-SCLC, which always has distant metastases, the
timing of TRT does not appear from the present
study to affect the prognosis.
Although our results are applicable for patients with
ES-SCLC, we recognize that there are limitations to the
study. First, because of the retrospective nature of this
analysis, there is unavoidable bias. Second, we acknow-
ledge that differences in radiation dose, and methods of
radiotherapy, second-line chemotherapy, and salvage
radiotherapy may have contributed to study bias.
Conclusion
In conclusion, after the start of first-line chemotherapy,
TRT can prolong survival of patients with ES-SCLC
without progression, and does not promote severe
toxicity. Receiving TRT early or late does not significantly
affect the prognosis, and the underlying mechanism is less
clear. Further prospective studies are recommended.
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